Intest Res.  2024 Jan;22(1):3-4. 10.5217/ir.2023.00198.

A novel serum biomarker of endoscopic mucosal healing in inflammatory bowel disease

• Kang HW

• KMID: 2551274
• DOI: http://doi.org/10.5217/ir.2023.00198

Reference

1. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011; 17:1415–1422.

2. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012; 18:1356–1363.

3. Le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving short- and long-term goals of management of inflammatory bowel diseases: getting it right, making it last. Gastroenterology. 2022; 162:1424–1438.

4. Sood A, Mahajan R, Singh A, Midha V, Mehta V. Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided? Intest Res. 2022; 20:297–302.

5. Kamat N, Vuyyuru SK, Kedia S, et al. Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis. Intest Res. 2022; 20:269–273.

6. Ripollés T, Martínez-Pérez MJ, Paredes JM, Vizuete J, Martin G, Navarro L. Submucosal fat accumulation in Crohn’s disease: evaluation with sonography. Intest Res. 2023; 21:385–391.

7. Lee SB, Kim HK, Park SH, Lim JH, Park SH. Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease. Intest Res. 2024; 22:75–81.